中国动脉硬化杂志2025，Vol.33Issue(7)：638-644,7.DOI:10.20039/j.cnki.1007-3949.2025.07.012
可溶性鸟苷酸环化酶激动剂在动脉粥样硬化性疾病中的研究进展
Research progress of soluble guanylate cyclase agonists in atherosclerotic diseases
摘要
Abstract
Atherosclerosis is a chronic inflammatory disease and the root cause of most cardiovascular diseases.Soluble guanylate cyclase(sGC)agonists play an important role in the regulation of atherosclerotic diseases by nitric oxide(NO)/sGC/cyclic guanosine phosphate(cGMP)signaling pathway.sGC plays an anti-atherosclerotic role in reducing blood lipid levels,improving endothelial dysfunction,reducing inflammatory responses,inhibiting platelet activation,in-hibiting smooth muscle cell proliferation and apoptosis via activating downstream cGMP.This article reviews the effect of sGC agonists on atherosclerosis and its mechanism,in order to provide a theoretical basis for the clinical application of sGC agonists.关键词
可溶性鸟苷酸环化酶/可溶性鸟苷酸环化酶激动剂/动脉粥样硬化性疾病Key words
soluble guanylate cyclase/soluble guanylate cyclase agonists/atherosclerotic disease分类
医药卫生引用本文复制引用
夏晴,沈军,蔡梦阳,蒋元英..可溶性鸟苷酸环化酶激动剂在动脉粥样硬化性疾病中的研究进展[J].中国动脉硬化杂志,2025,33(7):638-644,7.基金项目
浙江省中医药科技项目(2024ZL140) （2024ZL140）
杭州市医药卫生科技项目(B20240578) （B20240578）
临平区科技计划项目(LPWJ20230205) （LPWJ20230205）
